The role of rare variants in LMNA as causative mutations in Arrhythmogenic Right Ventricular Cardiomyopathy is described below. By comparing the frequency of LMNA variants in large ARVC clinical cohorts to the background population rate in the ExAC database, the proportion of ARVC patients with pathogenic mutations in LMNA can be estimated, as well as the likelihood that a rare (population allele frequency <0.0001) LMNA variant identified in a ARVC patient is disease-causing. Summary data for different variant classes (all protein-altering variants, loss of function truncating variants and non-truncating variants) is highlighted - see the table below for full details of this analysis.
Excess of LMNA variants in ARVC: -0.62% (p=1.0000)
Based on an analysis of all rare protein-altering variants (MAF<0.0001 in ExAC) in LMNA found in 93 ARVC samples sequenced by OMGL and in reference samples of the ExAC population database. As there is no excess burden of variation in the disease cohort, this analysis suggests that LMNA variants do not contribute to ARVC. Please note as this is based on a small ARVC cohort, the data should be used with caution.
|Excess in ARVC||-0.62%
0.00 - 6.59
0.00 - 266.67
0.00 - 6.76
The Etiological Fraction (EF) is the proportion of affected carriers where the variant caused ARVC. The Odds Ratio (OR) describes the odds of having a rare variant in the patient cohort to the odds in the ExAC cohort. Fisher's exact test p-values are displayed for case excess, 95% confidence intervals for EFs and ORs.
1. Roddy Walsh, Kate L. Thomson, James S. Ware, Birgit H. Funke, Jessica Woodley, Karen J. McGuire, Francesco Mazzarotto, Edward Blair, Anneke Seller, Jenny C. Taylor, Eric V. Minikel, Exome Aggregation Consortium, Daniel G. MacArthur, Martin Farrall, Stuart A. Cook and Hugh Watkins. Reassessment of Mendelian gene pathogenicity using 7,855 cardiomyopathy cases and 60,706 reference samples. Genet Med. 2016 doi:10.1038/gim.2016.90.